Fareston use restricted

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the use of Fareston (toremifene) should be restricted.

The CHMP reviewed Fareston due to concerns over its cardiovascular effects, in particular the concern that it could cause prolongation of the QT interval.

The Committee concluded that the benefits of toremifene outweigh its risks for the treatment of hormone-dependent metastatic postmenopausal breast cancer, but that its use should be resricted.

Toremifene should no longer be used in patients with prolonged QT intervals, electrolyte disturbances, clinically relevant bradycardia, heart failure with reduced left-ventricular ejection fraction or a history of symptomatic arrhythmias. In addition, it should not be used with other medicines that prolong the QT interval.

View Fareston drug record

Further information: EMEA Q&A on Fareston review

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in